VRX


Mizuho Sets Expectations on Valeant (VRX) Ahead of Earnings

Valeant (NYSE:VRX) is raring to deliver what Mizuho’s Irina Rivkind Koffler expects will be a solid second quarter print, with the potential for a …

Valeant (VRX) Gets a Price Target Hike on Back of Xifaxan Growth Potental

Shares of Valeant (NYSE:VRX) sold off recently after the FDA gave a no-go to the company’s plaque psoriasis treatment Duobrii. The FDA’s issuance of …

Are Things Looking Up for Valeant Pharmaceuticals (VRX)?

After June, you won’t have Valeant (NYSE:VRX) to kick around anymore. The Canada-based drug company will be changing its name to Bausch Health Companies, …

Valeant Pharmaceuticals’ (VRX) Salix and US WorldMeds Sign Co-Promotion Agreement for Opioid Withdrawal Treatment LUCEMYRA

Valeant Pharmaceuticals (NYSE:VRX) wholly owned subsidiary Salix and US WorldMeds announced today that they have entered into an exclusive agreement to co-promote US WorldMeds’ LUCEMYRA™ …

A Balanced Take on Valeant (VRX) Following Yesterday’s Sell-Off

Valeant (NYSE:VRX) shares fell 12% yesterday on news that the FDA issued a complete response letter (CRL) concerning the drug maker’s plaque psoriasis …

We Still Like Valeant (VRX) Stock Here, Says Healthcare Analyst Louise Chen

Looking for a reason to buy shares of Valeant? How about three reasons, courtesy of Cantor analyst Louise Chen.

Mizuho Remains Bullish on Valeant (VRX) Shares Following FDA Setback

Valeant (NYSE:VRX) shares are dipping 6% in early trading Monday, after the drug maker announced that it has received a Complete Response Letter (CRL) …

Valeant (VRX): Getting Better? Maybe

While Valeant shows signs of a rebound, RBC Capital’s Douglas Miehm remains sidelined.

Valeant (VRX) Hopes Name Change Will Improve Luck, But ‘Full Recovery’ in Dermatology Still Needed, Says BTIG

On back of a solid swing for VRX’s rebounding momentum, BTIG’s Tim Chiang sheds light on Q1 earnings and a forthcoming name change.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts